SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a recent announcement of a $250 million private placement and a $20 million strategic investment related to a Worldcoin treasury strategy, leading to a massive surge in stock price. The community is actively discussing potential price targets and whether other stocks might follow a similar trajectory, while some express caution about a possible pump and dump scenario. Chatter revolves around the stock's extreme volatility and potential for further gains or losses.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Sentage Holdings Inc. ($SNTG) is trending due to significant price volatility and trading halts, sparking discussions around potential short squeezes. The community is comparing its movements to other high-flying stocks like $OCTO and $INHD, with some suggesting a similar parabolic run. Traders are actively debating entry and exit points amidst the stock's volatile swings.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities (ASST) is trending due to community excitement surrounding a potential merger and its possible transition into a Bitcoin treasury, drawing comparisons to $OCTO's recent surge. The community is actively discussing high short interest, potential for a squeeze, and the upcoming vote, while also debating the involvement of Vivek Ramaswamy. Some traders are interpreting dark pool data as a sign of institutional accumulation and a potential breakout staging.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending amid discussions around its correlation to crypto markets and AI data center prospects, with some traders expressing frustration over its price action and potential manipulation. The community is debating its valuation and future performance, particularly in relation to upcoming earnings and Helios updates. There's also a notable back-and-forth between users, creating buzz around the stock.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending after showcasing its solid-state battery technology in a Ducati motorcycle, sparking optimism about real-world applications and faster charging capabilities. The community is buzzing about potential partnerships with other OEMs and the possibility of a 'short squeeze', while also considering the broader implications for the EV battery market and QuantumScape's long-term value. Recent volume and options activity suggest growing interest in the stock.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending as the community debates its recent pullback and potential for future growth, fueled by discussion around short sellers and comparisons to other meme stocks like OCTO. Bulls are actively defending their positions, dismissing bearish sentiments as temporary noise amidst anticipation for upcoming catalysts. Some traders believe a new CEO or a major deal could be announced soon.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending due to a mix of factors including speculation around upcoming investor conferences and the impending expiration of Carvana's warrants. Community members are debating the company's valuation compared to competitors like LMND, while others discuss the potential for a short squeeze. Despite some negative sentiment regarding management and near-term profitability, some investors believe ROOT is undervalued given its growth potential and partnerships.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amid discussions of an upcoming event and potential iPhone 17 launch, with community members weighing in on positive catalysts and possible short squeezes. A court ruling impacting a Google search deal is also drawing attention, with analysts discussing implications for Apple's services revenue. Bullish sentiment is fueled by record sales in India, while some remain cautious ahead of potential news events.

36Kr Holdings, Inc. operates as an online media publisher company. It offers business services, including online advertising services, enterprise value-added services and subscription services. The company was founded by Cheng Cheng Liu on December 3, 2018 and is headquartered in Beijing, China.

36Kr Holdings Inc - ADR

36Kr Holdings

Shares of KRKR are seeing significant volatility and multiple trading halts, generating buzz among traders. Community members are actively comparing KRKR to other stocks that have experienced similar rapid gains, with some suggesting it could be the "next" big runner. Some traders caution about pump-and-dump schemes.

Knightscope, Inc. engages in the provision and development of security technology solutions. Its product portfolio includes the K1 stationary machine, the K3 indoor machine, the K5 outdoor machine, and the K7 multi-terrain four-wheel vehicle. Its machines patrol client sites without the need for remote control to provide a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area, and deter crime. The company was founded by William Santana Li and Stacy Dean Stephens on April 4, 2013 and is headquartered in Sunnyvale, CA.

Knightscope Inc - Ordinary Shares - Class A

Knightscope ($KSCP) is trending due to discussions around leadership changes and perceived struggles in the robotics industry, particularly in comparison to competitor AITX. Community sentiment suggests concerns about KSCP's performance and leadership, with some pointing to AITX as a stronger player in the autonomous robotics space. There are also mentions of a capital raise and price target updates influencing the stock's movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Equity

Telomir Pharmaceuticals' anti-aging expert to present pre-clinical data

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase...

UPDATE   Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1  to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times...

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditionsBALTIMORE, March 14, 2024 (GLOBE NEWSWIRE...

Telomir Pharmaceuticals presents preclinical data for Telomir-1

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related...

Telomir Pharmaceuticals announces Roizen to increase role at company

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TELO News

TELO Telomir Pharmaceuticals Inc